Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-HER2 TKI vs Pertuzumab in HER2+ Breast Cancer with Brain Metastases
NCT04760431Phase 2Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Oct 2021
- Primary completion
- Sep 2024
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in HER2-positive breast cancer and brain metastases (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Objective Response Rate at 3 years. Status: unknown.
02
Conditions
HER2-positive breast cancerbrain metastases
Beyond the preview
Go deeper on NCT04760431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04760431.